Literature DB >> 22977215

Lupus nephritis: is the kidney biopsy currently necessary in the management of lupus nephritis?

Giovanna Giannico1, Agnes B Fogo.   

Abstract

Most patients with SLE develop kidney disease related to this systemic underlying disease process. Lupus nephritis is an important cause of morbidity and even mortality in patients with systemic lupus erythematosus. Lupus nephritis has diverse morphologic manifestations with varying clinical presentations and consequences. The pathogeneses involve immune complexes, which can deposit anywhere in the kidney, and other mechanisms, including endothelial injury, podocytopathy, and tubulointerstitial injury. Treatment and prognosis accordingly range from excellent even with only observation with minimal mesangial deposits, to kidney failure despite aggressive immunosuppression in patients with severe proliferative disease. Renal biopsy plays a crucial role in the diagnosis of the specific form of lupus nephritis in any patient. However, the role of the renal biopsy in prediction of outcome, treatment, and prognosis has been controversial. We will review the current classification of lupus nephritis and the value of renal biopsy in the management of these patients.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22977215     DOI: 10.2215/CJN.03400412

Source DB:  PubMed          Journal:  Clin J Am Soc Nephrol        ISSN: 1555-9041            Impact factor:   8.237


  30 in total

1.  Lupus Nephritis in the Era of Biomarkers.

Authors:  Jose Manuel Monroy Trujillo; Derek Michael Fine
Journal:  Clin J Am Soc Nephrol       Date:  2015-12-23       Impact factor: 8.237

2.  Histopathological indicators of disease outcome in class IV lupus nephritis: a revisit of various indices.

Authors:  Manish Rathi; Krishan Lal Gupta; Kusum Joshi; Pramod K Gupta; Aman Sharma; Harbir Singh Kohli; Vivekanand Jha; Vinay Sakhuja
Journal:  Rheumatol Int       Date:  2015-03-11       Impact factor: 2.631

3.  Identification, Confirmation, and Replication of Novel Urinary MicroRNA Biomarkers in Lupus Nephritis and Diabetic Nephropathy.

Authors:  Mariana Cardenas-Gonzalez; Anand Srivastava; Mira Pavkovic; Vanesa Bijol; Helmut G Rennke; Isaac E Stillman; Xiaolan Zhang; Samir Parikh; Brad H Rovin; Maryam Afkarian; Ian H de Boer; Jonathan Himmelfarb; Sushrut S Waikar; Vishal S Vaidya
Journal:  Clin Chem       Date:  2017-06-30       Impact factor: 8.327

4.  Is serum uric acid a predictor of long-term renal outcome in lupus nephritis?

Authors:  Michelle Remião Ugolini-Lopes; Samara S Gavinier; Elaine Leon; Vilma Trindade Viana; Eduardo Ferreira Borba; Eloisa Bonfá
Journal:  Clin Rheumatol       Date:  2019-06-02       Impact factor: 2.980

5.  Urinary clusterin-a novel urinary biomarker associated with pediatric lupus renal histopathologic features and renal survival.

Authors:  Chao-Yi Wu; Huang-Yu Yang; Hui-Ping Chien; Min-Hua Tseng; Jing-Long Huang
Journal:  Pediatr Nephrol       Date:  2018-03-06       Impact factor: 3.714

6.  Role of renal expression of CD68 in the long-term prognosis of proliferative lupus nephritis.

Authors:  Cristiane B Dias; Patrícia Malafronte; Jin Lee; Aline Resende; Lectícia Jorge; Cilene C Pinheiro; Denise Malheiros; Viktoria Woronik
Journal:  J Nephrol       Date:  2015-11-30       Impact factor: 3.902

7.  The expression of EBV-encoded LMP1 in young patients with lupus nephritis.

Authors:  Yan Ding; Xiaojie He; Wang Liao; Zhuwen Yi; Huilan Yang; Wei Xiang
Journal:  Int J Clin Exp Med       Date:  2015-04-15

Review 8.  Biomarkers for kidney involvement in pediatric lupus.

Authors:  Beatrice Goilav; Chaim Putterman; Tamar B Rubinstein
Journal:  Biomark Med       Date:  2015       Impact factor: 2.851

9.  Studying IFN-gamma, IL-17 and FOXP3 in pediatric lupus nephritis.

Authors:  Mutlu Uysal Yazici; Diclehan Orhan; Gulsev Kale; Nesrin Besbas; Seza Ozen
Journal:  Pediatr Nephrol       Date:  2014-01-31       Impact factor: 3.714

Review 10.  The pathogenesis, diagnosis and treatment of lupus nephritis.

Authors:  Noa Schwartz; Beatrice Goilav; Chaim Putterman
Journal:  Curr Opin Rheumatol       Date:  2014-09       Impact factor: 5.006

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.